Adverse reactions similar to placebo
Adverse reactions (ARs) occurring in at least 2% and at a frequency greater than placebo
MOH=medication overuse headache.
*In regard to MOH and other safety concerns, the safety of treating more than 8 migraines in a 30-day period has not been established.
1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2021. 2. Data on file. Allergan. 3. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152.